Oral complex aphthous. Recurrent oral aphthae
Conditions
Interventions
Intervention group:Consumption of 2 oral sina Curcumin capsule 40 mg once a day for 1 month.
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients between the ages of 20 and 60 years Complex aphthous ulcers, which include: a number of painful aphthous lesions on the oral mucosa that appear intermittently and heal slowly; Created in less than 72 hours
Exclusion criteria
Exclusion criteria: Patients taking topical medication to treat the aphthous in the last two weeks or taking systemic medication in the last one month Patients with systemic diseases such as intestinal and gastric diseases (Crohn's and ulcerative colitis), Behcet's disease, Reiter's syndrome and gallstones Patients with anxiety disorders Patients with bracets Pregnant and lactating women Patients with a history of alcohol and drug use Patients treated with immunosuppressants, chemotherapy, and immunomodulatory drugs over the past year History of allergies to plant compounds, including turmeric High liver enzymes Use of anticoagulants or antiplatelets (curcumin has an inhibitory effect on platelet aggregation) such as Warfarin, Aspirin, Clopidogrel, Epixaban, Rivaroxaban, Heparin and Enoxaparin History of gastric ulcer and duodenal ulcer Patients with inadequate literacy who do not understand the consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional complications. Timepoint: At the beginning of treatment and 2 weeks, 4 weeks and 8 weeks after consumption of the medicine. Method of measurement: Use of visual analoge scale (VAS) from 0-10. 0: The least discomfort and interference of the lesions with the patient speaking, chewing and brushing. 10: The highest amount of interference.;The recurrence of ulcers. Timepoint: 2, 4 and 8weeks after consumption of the medicine. Method of measurement: With physical examination of patients and based on the time after taking the drug that the disease will occurs again.;The number of aphthous lesion. Timepoint: At the beginning of treatment and 2 weeks, 4 weeks and 8 weeks after consumption of the medicine. Method of measurement: Count the number of lesions through examination.;Patient satisfaction with treatment. Timepoint: 2, 4 and 8weeks after consumption of the medicine. Method of measurement: Use of visual analoge scale. 0-7: Dissatisfaction 8-10: Satisfaction. | — |
Secondary
| Measure | Time frame |
|---|---|
| The size of aphthous lesion. Timepoint: At the beginning of treatment and 2 weeks, 4 weeks and 8 weeks after consumption of the medicine. Method of measurement: Using a sterile vernier caliper.;The severity of pain. Timepoint: At the beginning of treatment and 2 weeks, 4 weeks and 8 weeks after consumption of the medicine. Method of measurement: Use of visual analoge scale (VAS) from 0-10. 0:no pain - 10: severe pain. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Seyed Javad Kia
Rasht University of Medical Sciences
Outcome results
None listed